| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/24/2011 | CA2266640C Methods for treating an ischemic disorder and improving stroke outcome |
| 05/19/2011 | WO2011059037A1 Pharmaceutical composition for external use |
| 05/19/2011 | WO2011058993A1 Method for screening for novel bone resorption inhibitor |
| 05/19/2011 | WO2011058988A1 Antiviral agent-supporting sheet and method for producing same |
| 05/19/2011 | WO2011058943A1 Pharmaceutical composition formed from combining compound having mch r1 antagonist activity and compound having npy y5 antagonist activity |
| 05/19/2011 | WO2011058508A2 New compositions for the treatment of chemioresitant and/or potentially chemioresistant leukaemias |
| 05/19/2011 | US20110118825 Anti-angiogenic compositions and methods of use |
| 05/19/2011 | US20110118279 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors |
| 05/19/2011 | US20110117105 Method of treating immune disease using b-cell antibodies |
| 05/19/2011 | US20110117057 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 05/19/2011 | US20110117030 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections |
| 05/19/2011 | DE102010048788A1 Transdermal system, useful e.g. as monotherapy for indicating e.g. multiple sclerosis, comprises immunomodulator as active agent and active agent-impermeable removable protective coating, adhesive layer and active agent permeable membrane |
| 05/19/2011 | CA2780941A1 Immediate release tablet formulations |
| 05/19/2011 | CA2780860A1 Pharmaceutical composition for external use |
| 05/19/2011 | CA2780144A1 Composition and methods for affecting cytokines and nf-kb |
| 05/18/2011 | EP2322929A1 Diagnostics, drug screening and treatment for cancer |
| 05/18/2011 | EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy |
| 05/18/2011 | EP2322603A1 Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| 05/18/2011 | EP2322243A1 Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium |
| 05/18/2011 | EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof |
| 05/18/2011 | EP2322226A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/18/2011 | EP2322225A1 Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
| 05/18/2011 | EP2322224A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 05/18/2011 | EP2322223A1 Therapeutic agent for migraine |
| 05/18/2011 | EP2322222A1 Therapeutic agent for irritable bowel syndrome |
| 05/18/2011 | EP2322216A1 A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| 05/18/2011 | EP2322199A1 Growth differentiation factor receptors, and methods of using same |
| 05/18/2011 | EP2322182A1 Androstenol derivatives as androgen receptor modulator |
| 05/18/2011 | EP2322179A1 Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders |
| 05/18/2011 | EP2322177A1 Use of a preparation based on nifedipine for treating vaginismus |
| 05/18/2011 | EP2322175A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 05/18/2011 | EP2322174A2 Combined use of valsartan and calcium channel blockers for therapeutic purposes |
| 05/18/2011 | EP2322169A1 Composition containing a DHA oil for use in the treatment of cystic fibrosis |
| 05/18/2011 | EP2322165A1 Apo2 ligand/TRAIL formulations |
| 05/18/2011 | EP2322161A1 Composition for preventing and treating odontostomatological pathologies of animals |
| 05/18/2011 | EP2322157A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
| 05/18/2011 | EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 05/18/2011 | EP2322151A2 Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor |
| 05/18/2011 | EP2322150A2 Method of identifying GLP-1 secretagogues |
| 05/18/2011 | EP2320948A1 Methods for treating reperfusion injuries |
| 05/18/2011 | EP2320911A1 Vasoconstriction compositions and methods of use |
| 05/18/2011 | EP2320903A1 THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| 05/18/2011 | EP2320892A2 Combination products |
| 05/18/2011 | EP2320884A2 Phosphate binding materials and their uses |
| 05/18/2011 | EP2320881A1 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
| 05/18/2011 | EP2320867A2 Preparations based on artemisia annua, the conversion thereof into microparticles and nanoparticles, and use of same |
| 05/18/2011 | EP2040755B1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| 05/18/2011 | EP2034967B1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 05/18/2011 | EP1589945B1 Topical pharmaceutical and/or cosmetic dispense systems |
| 05/18/2011 | EP1553967B1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 05/18/2011 | EP1356298B1 Diagnosis of disease |
| 05/18/2011 | EP1131440B1 Process for oxidising terpenes |
| 05/18/2011 | CN1665554B Compounds and method for preparing surfaces in a haemocompatible manner |
| 05/18/2011 | CN1527704B Compositions and method of administering tubulin binding agents for the treatment of ocular diseases |
| 05/18/2011 | CN102066945A Modulators of STAT3 signalling |
| 05/18/2011 | CN102065898A New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| 05/18/2011 | CN102065897A New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| 05/18/2011 | CN102065896A Analgesic anti-inflammatory preparation for external application |
| 05/18/2011 | CN102065865A Multiple myeloma treatments |
| 05/18/2011 | CN102065856A Combination of dronedarone with at least one diuretic, and therapeutic use thereof |
| 05/18/2011 | CN102065854A Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders |
| 05/18/2011 | CN102058889A Dispersible tablet containing anticoagulants and application thereof |
| 05/18/2011 | CN102058888A Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof |
| 05/18/2011 | CN102058887A Application of P2Y4 receptor stimulant in preparing medicaments for treating Alzheimer's disease |
| 05/18/2011 | CN102058886A Medical powder inhalation and application thereof |
| 05/18/2011 | CN102058885A Combination therapy of lower urinary tract disorders with Alpha2Delta ligands and NSAIDs |
| 05/18/2011 | CN102058533A Method for preparing liposome micro-capsules and application thereof |
| 05/18/2011 | CN101559228B Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia |
| 05/18/2011 | CN101461821B Compound oral medicament composition for treating respiratory diseases of pig and cattle |
| 05/18/2011 | CN101242829B Pharmaceutical composition comprising PPAR regulator |
| 05/17/2011 | US7943760 Non-nucleotide composition for inhibiting platelet aggregation |
| 05/17/2011 | US7943627 2,4-diaminopyrimidine derivatives |
| 05/17/2011 | US7943603 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 05/17/2011 | US7943593 Compositions comprising inhibitors of IMPDH enzyme |
| 05/17/2011 | US7943588 Method for preventing or treating neuropathic pain |
| 05/17/2011 | US7943575 Sustained release drug formulations containing a carrier peptide |
| 05/17/2011 | US7943338 Autoimmune conditions and NADPH oxidase defects |
| 05/17/2011 | US7943316 Immunostimulatory oligonucleotides and uses thereof |
| 05/17/2011 | US7943292 Physiologically acceptable aqueous solutions and methods for their use |
| 05/17/2011 | US7943147 dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants |
| 05/17/2011 | US7943134 Compositions and methods for identifying response targets and treating flavivirus infection responses |
| 05/17/2011 | US7943118 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 05/17/2011 | CA2484374C Medical products comprising a haemocompatible coating, production and use thereof |
| 05/17/2011 | CA2470365C 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| 05/17/2011 | CA2437851C 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 05/17/2011 | CA2425489C Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 05/17/2011 | CA2414484C Muscle-strengthening drugs and anti-inflammatory drugs |
| 05/17/2011 | CA2401385C Protein matrix materials, devices and methods of making and using thereof |
| 05/17/2011 | CA2397194C Alpha v integrin receptor antagonists |
| 05/17/2011 | CA2368470C Medical devices and applications of polyhydroxyalkanoate polymers |
| 05/17/2011 | CA2308007C Enhancer for antibody to lymphocytic tumors |
| 05/12/2011 | WO2011057183A1 Nutritional supplements for relief of dry eye |
| 05/12/2011 | WO2011055550A1 Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
| 05/12/2011 | WO2011034509A3 New benzathine salts of ace inhibitors, process for their preparation and their use for the treatment of cardiovascular diseases |
| 05/12/2011 | WO2007034509A3 Recombinant granulocyte-colony stimulating factor formulation and process |
| 05/12/2011 | US20110112283 Rna interference mediating small rna molecules |
| 05/12/2011 | US20110111528 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 05/12/2011 | US20110111057 Methods and Compounds Useful to Induce Apoptosis in Cancer Cells |
| 05/12/2011 | US20110111034 Method and material for enhanced tissue-biomaterial integration |
| 05/12/2011 | US20110111016 Non-dna base-containing polynucleotide compositions and their use for the modulation of immune responses |